ACROMEGALY

Authored by

Mohammed looti

November 18, 2025

Introduction and Definition of Acromegaly

Acromegaly, derived from the Greek words meaning "extremity" and "enlargement," is a rare, chronic endocrine disorder characterized by the excessive production of **Growth Hormone (GH)** in adulthood. This overproduction typically stems from a benign tumor of the pituitary gland, known as a pituitary adenoma. The condition results in the insidious, progressive enlargement of specific skeletal appendages, notably the hands and feet, alongside noticeable changes in the structure of the cranium and facial features. Unlike many common illnesses, acromegaly is characterized by its slow onset, often leading to significant diagnostic delays, sometimes lasting years, because the physical changes are subtle and gradually attributed to the normal aging process by both patients and, initially, healthcare providers.

The distinction between acromegaly and its pediatric counterpart, **gigantism**, is crucial and hinges entirely upon the patient's skeletal maturity. In children and adolescents who have not yet undergone epiphyseal plate fusion--meaning their skeletal development is still active--the excessive GH causes proportionate growth, leading to extraordinary height, a condition termed gigantism. Conversely, acromegaly manifests only in adults whose growth plates have closed, preventing further longitudinal growth. Instead of increasing height, the persistent hormonal excess stimulates the proliferation of soft tissues, cartilage, and periosteal bone growth, leading to the characteristic disfigurement and serious systemic complications that define the adult presentation.

The underlying mechanism involves the hypothalamic-pituitary axis. Elevated GH stimulates the liver to produce high quantities of **Insulin-like Growth Factor 1 (IGF-1)**. IGF-1 is the primary mediator of GH action, responsible for promoting cell growth and proliferation throughout the body. Therefore, acromegaly is fundamentally a state of chronic IGF-1 excess. The disease is statistically uncommon, affecting an estimated 50 to 70 people per million globally, making awareness of its subtle presentation essential for early intervention and mitigation of the severe morbidity associated with untreated disease.

Etiology: The Pituitary Adenoma

In approximately 98% of all diagnosed cases, acromegaly is caused by a somatotroph adenoma--a benign tumor arising from the acidophil cells (somatotrophs) of the anterior pituitary gland that secrete GH. These tumors are usually monoclonal, arising from a single transformed cell, and are almost always sporadic, meaning they occur without a known familial pattern. While the precise molecular events leading to adenoma formation are complex, genetic mutations are often implicated. A key finding in many GH-secreting tumors is a mutation in the Gs alpha subunit protein (*GNAS* gene), which leads to constitutive activation of cyclic adenosine monophosphate (cAMP) signaling, resulting in uncontrolled GH secretion independent of normal hypothalamic regulation.

Pituitary adenomas are classified by size: microadenomas (less than 10 mm in diameter) and macroadenomas (10 mm or greater). Most patients with acromegaly present with macroadenomas, reflecting the long period of silent growth before diagnosis. These larger tumors can exert mass effects on surrounding structures, leading to secondary symptoms. For instance, compression of the optic chiasm frequently causes visual field defects, particularly **bitemporal hemianopsia**. Furthermore, mass effect on the remaining healthy pituitary tissue can inhibit the secretion of other vital hormones, leading to deficiencies such as hypothyroidism, hypogonadism, or hypocortisolism, which require separate management.

Rarely, acromegaly can be caused by ectopic GH or GHRH (Growth Hormone Releasing Hormone) secretion. Ectopic GH production is extremely rare and usually involves non-pituitary tumors, such as pancreatic or lung carcinoids. Ectopic GHRH secretion, while also rare, stimulates the normal pituitary somatotrophs to overproduce GH, resulting in hyperplasia rather than a primary adenoma. Identifying the etiology is paramount because the treatment approach, particularly surgical intervention, differs significantly when the source of the hormonal excess is outside the sella turcica.

Clinical Manifestations: Skeletal and Connective Tissue Changes

The most recognizable signs of acromegaly involve progressive changes to the skeletal system and soft tissues. The enlargement of the extremities is almost universal; patients require increasingly larger shoe and glove sizes, often being the first indication noticed by family members or the patient themselves. Hands become doughy, thick, and broad, while the fingers display a characteristic "sausage-like" appearance. Facial changes are equally distinctive, encompassing **mandibular prognathism** (protrusion of the lower jaw), broadening of the nose, thickening of the lips, and widening of the interdental spaces, contributing significantly to changes in physical appearance and potential psychological distress.

Beyond aesthetic changes, skeletal remodeling causes severe orthopedic issues. Arthropathy (joint disease) is highly prevalent, particularly affecting the large weight-bearing joints (knees, hips, shoulders) and the spine. The chronic excess of GH and IGF-1 promotes cartilage and synovial hypertrophy, leading to joint pain, reduced mobility, and early-onset osteoarthritis. Spinal changes often include vertebral enlargement and ligamentous hypertrophy, which can lead to spinal stenosis and nerve compression, necessitating complex neurosurgical interventions in severe cases.

Soft tissue involvement extends beyond the extremities and face. The tongue often becomes enlarged (macroglossia), which can interfere with speech, swallowing, and, crucially, contribute significantly to the development of **obstructive sleep apnea (OSA)**. OSA is a major comorbidity in acromegaly, resulting from both macroglossia and the thickening of the pharyngeal tissues. If left

untreated, OSA contributes to chronic fatigue, daytime somnolence, and exacerbates cardiovascular risk factors, making screening and management of sleep disorders a critical aspect of comprehensive care.

Systemic Complications and Cardiovascular Risk

Acromegaly is not merely a cosmetic disorder; it is associated with profound systemic complications that dramatically increase morbidity and mortality if the disease remains active. Cardiovascular disease is the leading cause of death in patients with untreated acromegaly. Chronic exposure to high levels of GH and IGF-1 induces a specific cardiomyopathy known as acromegalic cardiomyopathy, characterized by biventricular hypertrophy, diastolic dysfunction, and eventual systolic failure. This condition often leads to arrhythmias, hypertension, and congestive heart failure.

Metabolic disturbances are also central to the pathology. GH is inherently an anti-insulin hormone, meaning its excess impairs glucose utilization in peripheral tissues, leading to insulin resistance. Consequently, **Type 2 diabetes mellitus** is a common comorbidity, occurring in approximately 20% to 50% of acromegaly patients. Management of hyperglycemia is often challenging and requires strict control to mitigate the risk of microvascular and macrovascular complications. Additionally, dyslipidemia, characterized by elevated triglycerides and reduced HDL cholesterol, further compounds the cardiovascular risk profile of these patients.

Furthermore, there is a recognized increase in the risk of certain malignancies, although the exact causal link remains under scrutiny. The chronic proliferative stimulus provided by high IGF-1 levels is theorized to promote oncogenesis. Colorectal polyps and cancer are of particular concern, necessitating regular screening via colonoscopy in all patients diagnosed with acromegaly. The overall goal of therapeutic intervention in acromegaly is not only to reverse cosmetic changes but, more importantly, to normalize GH and IGF-1 levels rapidly to halt and potentially reverse the progression of these life-threatening systemic complications.

Psychological Impact and Quality of Life

The slow, progressive nature of the physical changes associated with acromegaly often leads to significant psychological distress and a severe reduction in **Quality of Life (QoL)**. Because the disease typically develops over many years, patients often experience feelings of alienation, self-consciousness, and depression related to their changing appearance and the lack of recognition of their condition by the medical community during the diagnostic delay period. The noticeable facial and bodily alterations can lead to social withdrawal and difficulty maintaining professional and personal relationships.

Beyond body image issues, the symptoms themselves contribute heavily to impaired QoL. Chronic

joint pain, persistent fatigue related to OSA, headaches caused by the pituitary mass, and muscle weakness (acromegalic myopathy) severely limit physical activity and daily functioning. Even after successful biochemical control is achieved through treatment, many patients continue to report lower QoL scores compared to the general population, emphasizing the need for comprehensive post-treatment support addressing chronic pain management, psychological counseling, and rehabilitation services.

Cognitive function, while generally preserved, may be subtly affected, particularly regarding memory and executive function, though these findings are often intertwined with the effects of comorbidities like sleep deprivation and hypopituitarism caused by the tumor. It is essential for clinicians managing acromegaly to recognize that treating the hormonal imbalance is only the first step; long-term care must incorporate mental health support to help patients adjust to residual physical changes and manage chronic symptoms that may persist despite biochemical normalization.

Diagnosis and Biochemical Confirmation

Diagnosis requires both clinical suspicion based on the characteristic physical signs and definitive biochemical confirmation of GH and IGF-1 hypersecretion. Due to the pulsatile nature of GH secretion, random measurement of GH is unreliable. The gold standard for confirming autonomous GH secretion is the **Oral Glucose Tolerance Test (OGTT)**. Normally, the ingestion of 75g of glucose suppresses GH levels to undetectable limits (below 0.4 ng/mL). In patients with acromegaly, the GH level fails to suppress below this threshold, confirming the diagnosis.

Simultaneous measurement of **IGF-1 levels** provides crucial complementary information. Because IGF-1 is stable throughout the day and reflects the integrated GH secretion over the preceding 24 hours, persistently elevated IGF-1 levels are highly diagnostic and serve as the primary biochemical marker for monitoring disease activity and treatment efficacy. The IGF-1 level must be interpreted relative to age- and sex-matched normative data, as normal ranges decline significantly with age.

Once biochemical confirmation is established, magnetic resonance imaging (MRI) of the pituitary gland is mandatory to localize the adenoma, determine its size, and assess its relationship to critical structures like the optic chiasm and cavernous sinuses. This imaging is vital for surgical planning. If the pituitary MRI is negative, which is extremely rare, clinicians must investigate potential ectopic sources of GH or GHRH, often requiring imaging of the chest and abdomen, and measurement of circulating GHRH levels.

Treatment Modalities: Surgery, Medical, and Radiation

The primary goal of treatment is to normalize GH and IGF-1 levels, shrink the tumor size, alleviate

mass effects, and preserve remaining pituitary function. Treatment is typically multimodal, involving surgical, medical, and sometimes radiation therapy.

Transsphenoidal Surgery: This is generally the first-line therapy for most patients. The procedure involves removing the adenoma through an incision made via the sphenoid sinus, leading to high cure rates, particularly for smaller tumors (microadenomas). Immediate cure rates for microadenomas can exceed 80%, though for macroadenomas, the success rate is lower, often requiring subsequent medical therapy due to residual tumor tissue.

Medical Therapy: Pharmacological intervention is used for patients who are not surgical candidates, who fail to achieve remission post-surgery, or who have residual disease. The main classes of drugs include **Somatostatin Receptor Ligands (SRLs)**, such as octreotide and lanreotide, which mimic the action of endogenous somatostatin to inhibit GH secretion and often shrink tumor volume. A second class is the **GH Receptor Antagonists**, such as pegvisomant, which block the action of GH at the tissue level, effectively lowering IGF-1 but not necessarily reducing tumor size. Dopamine agonists (e.g., cabergoline) are less effective but may be used as adjunctive therapy, especially in co-secreting prolactinomas.

Radiation Therapy: Used as a third-line option for patients who fail both surgery and medical therapy, radiation (conventional or stereotactic radiosurgery) delivers focused doses to the pituitary tumor. While effective at gradually lowering GH and IGF-1 levels over several years, radiation carries a high risk of delayed hypopituitarism, often necessitating lifelong hormone replacement therapy.

Prognosis and Long-Term Management

The prognosis for patients with acromegaly has dramatically improved with advances in diagnostic techniques and therapeutic options. While untreated acromegaly leads to a significant reduction in life expectancy, often by 10 years or more, successful biochemical control--defined by achieving a normalized IGF-1 level and suppressed GH after OGTT--can normalize mortality rates, bringing them close to that of the general population. This highlights the critical importance of achieving remission.

Long-term management requires continuous, specialized endocrinological monitoring. This includes regular assessment of IGF-1 and GH levels, pituitary imaging to detect tumor recurrence, and diligent screening for comorbidities. Specific focus must be placed on managing cardiovascular risk factors, including hypertension and diabetes, and ensuring regular colon cancer surveillance.

Even in remission, certain physical changes, particularly skeletal remodeling like mandibular protrusion, may be irreversible. However, soft tissue swelling and thickening typically resolve,

leading to improved appearance and reduced symptoms like carpal tunnel syndrome and obstructive sleep apnea. The persistent need for management of chronic comorbidities and the psychological sequelae underscore the need for a multidisciplinary team approach involving endocrinologists, neurosurgeons, cardiologists, and mental health professionals to ensure optimal outcomes and maximum quality of life for the acromegaly patient.

In summary, acromegaly is a condition caused by chronic **growth hormone** hypersecretion in adults, leading to characteristic peripheral enlargement and severe systemic complications. Early diagnosis and aggressive multimodal treatment aimed at normalizing **IGF-1** levels are crucial for preventing irreversible organ damage and ensuring a favorable long-term prognosis, contrasting sharply with the historical outcomes associated with this debilitating disease.